Original news and analysis on international IP policy
European Trade Commissioner Cecilia Malmstroem, speaking to the President of the German Bundestag, Norbert Lammert, announced reading rooms for the consolidated texts of the Transatlantic Trade and Investment Partnership (TTIP) in all capitals of the EU member states.
CAPE TOWN, South Africa -- A law to regulate intellectual property derived from research and development conducted using public funds has boosted the number of patent applications filed and granted by universities and research institutions in the past five years.
The stretch run for Europe's Unitary Patent System (UPS) again took centre stage at the Premier Cercle IP Summit 2015 in Berlin yesterday. Eyes are on Germany for the ratification of the UPS. Cornelia Rudloff-Schäffer, president of the German Patent Office, in the keynote speech assured the 300 hundred participants Germany was preparing for the new system and called out to industry to prepare for the change, saying: “Check your portfolio now.”
Colombia has a decision to make. A full year has passed from the November 24, 2014 request by iFarma, Misión Salud and CIMUN for a declaration of the public interest regarding the cancer drug imatinib (marketed by Novartis as Gleevec/Glivec), the first step on the path toward a compulsory license in Colombia. Thus far, Colombia’s Ministry of Health and Social Protection has failed to act one way or another, leaving patients in limbo and the government at the mercy of a Swiss pharmaceutical giant that reported revenue of over $57.9 Billion USD in 2013, write James Love and Andrew S. Goldman.
A seminar on patents and availability of medicines in developing countries yesterday considered whether patents constitute a barrier to access. For the private sector, patents are essential to the innovation system, for others they maintain high prices and should be licensed for easier access. Beyond patents, biologics seem to be taking over the pharmaceutical industry, and the complexity of manufacturing biosimilars might well leave traditional generic manufacturers by the wayside.
Separately, a side event at WIPO looked at IP management strategies in private-public partnerships in agriculture and health technologies.
The final text of the Trans-Pacific Partnership confirms beyond doubt the apprehensions expressed by civil society, academia and the generic industry about new barriers to access to medicines. The TPP has done away with several flexibilities provided under the TRIPS Agreement and the Doha Declaration on Public Health. Though the text mentions “nothing in this [IPR] Chapter limits a Party’s rights and obligations under Article 31 of the TRIPS Agreement,” the TPP Investment Chapter overrides these flexibilities, says D G Shah.
The African Regional Intellectual Property Organization (ARIPO) recently held two top organ meetings in Lusaka, Zambia, to debate the organisation’s strategic plan for 2016-2020.
Two bipartisan United States senators today released the results of an 18-month investigation into the US$84,000 price of the Sovaldi hepatitis C drug, finding the pricing and marketing strategy was aimed at maximizing revenue at the expense of access and affordability. The new report also shows the high impact on US government drug procurement programs and other data.
COPENHAGEN, Denmark -- Having led the successful collaborative testing of an Ebola-vaccine in record time, John-Arne Røttingen of the Norwegian Institute of Public Health now wants to expand the idea to a permanent global financing facility for research and development. And he is optimistic.
The Medicines Patent Pool has signed a collaborative agreement with the University of Liverpool to develop HIV nanomedicines.
The World Intellectual Property Organization committee on patent law is meeting this week, including a half-day seminar on the relationship between patent systems and the availability of medicines in developing countries and least-developed countries.
The US government has been less than candid about the Trans-Pacific Partnership. While the agreement was being negotiated, the US Trade Representative stated that a much-criticized arbitration process included in the TPP would not apply to intellectual property. Turns out, it does apply to IP. And it provides foreign corporations with a huge advantage in IP disputes – private arbitrations that can override courts and statutes, effectively rewriting a nation’s IP laws.